Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients
NCT06483074Phase 2Recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Jul 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of empagliflozin in end stage renal disease (ESRD) (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoints: Recruitment rate, Medication adherence at 6 months and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT06483074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06483074.